SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

BRONTE, Giuseppe
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 559
AS - Asia 246
EU - Europa 102
SA - Sud America 15
Totale 922
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 558
SG - Singapore 109
CN - Cina 105
IT - Italia 64
ID - Indonesia 14
BR - Brasile 11
DE - Germania 8
AT - Austria 5
GB - Regno Unito 5
FI - Finlandia 4
NL - Olanda 4
CO - Colombia 3
PH - Filippine 3
AE - Emirati Arabi Uniti 2
FR - Francia 2
HK - Hong Kong 2
IE - Irlanda 2
LT - Lituania 2
TW - Taiwan 2
AZ - Azerbaigian 1
BD - Bangladesh 1
BG - Bulgaria 1
BH - Bahrain 1
CA - Canada 1
CZ - Repubblica Ceca 1
EE - Estonia 1
JO - Giordania 1
KG - Kirghizistan 1
LV - Lettonia 1
NP - Nepal 1
PK - Pakistan 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TR - Turchia 1
UY - Uruguay 1
Totale 922
Salva come PNG Salva come JPEG
Città #
Santa Clara 415
Singapore 44
Bologna 18
Fairfield 17
Ashburn 16
Jakarta 14
Cambridge 13
Woodbridge 6
Falkenstein 5
Ferrara 5
Forest City 5
Los Angeles 5
Houston 4
Lappeenranta 4
Milan 4
Palermo 4
Frattamaggiore 3
London 3
Manila 3
Rome 3
Seattle 3
Ann Arbor 2
Arezzo 2
Brasília 2
Careri 2
Dublin 2
Fort Worth 2
Hong Kong 2
Imola 2
Monza 2
Nuremberg 2
Paris 2
Prineville 2
Salerno 2
Sandston 2
Springfield 2
Vienna 2
Wilmington 2
Abaetetuba 1
Amman 1
Ankara 1
Baku 1
Barra de Guabiraba 1
Bishkek 1
Bratislava 1
Brescia 1
Buffalo 1
Chicago 1
Cornaredo 1
Dhaka 1
Florianópolis 1
Fortaleza 1
Frankfurt am Main 1
Hounslow 1
Indaiatuba 1
Jiaxing 1
Kathmandu 1
Kilburn 1
Lahore 1
Lisbon 1
Montevideo 1
Muriaé 1
Napa 1
Naples 1
Norwalk 1
Ottawa 1
Paracuru 1
Parma 1
Pittsburgh 1
Prague 1
Princeton 1
Riffa 1
Riga 1
Rio das Ostras 1
Salvador 1
Shanghai 1
Sofia 1
Tallinn 1
Volla 1
Totale 669
Salva come PNG Salva come JPEG
Nome #
Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer 76
Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients 28
Near-Complete Response to Osimertinib for Advanced Non-Small-Cell Lung Cancer in a Pretreated Patient Bearing Rare Compound Exon 20 Mutation (S768I + V774M): A Case Report 28
Immune Checkpoint Inhibitors in “Special” NSCLC Populations: A Viable Approach? 26
Immunotherapy of mesothelioma: the evolving change of a long-standing therapeutic dream 24
Healthcare Costs and Resource Utilisation of Italian Metastatic Non-Small Cell Lung Cancer Patients 20
High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis 20
Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients? 20
The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy 20
The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis 19
Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis 15
Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors 15
MicroRNAs in Colorectal Cancer Drug Resistance: Shooters become Targets 14
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future 14
A headlight on liquid biopsies: a challenging tool for breast cancer management 13
Anti-endothelin drugs in solid tumors 13
A phase II trial of fixed-dose rate gemcitabine plus capecitabine in metastatic/advanced biliary tract cancer patients 13
Relationship between imaging‐derived parameters and circulating microRNAs to study the degree of lung involvement in hospitalized geriatric patients with COVID‐19 pneumonia 13
Analysis of Germline gene copy number variants of patients with sporadic pancreatic adenocarcinoma reveals specific variations 13
Brigatinib in the first-line treatment of ALK+ metastatic NSCLC: safety and efficacy 13
Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? 13
The great need to overcome osimertinib resistance in advanced non-small cell lung cancer: from combination strategies to fourth-generation tyrosine kinase inhibitors 13
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward 13
Bortezomib: A new pro-apoptotic agent in cancer treatment 13
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 13
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 12
ALK and crizotinib: After the honeymoon...what else? Resistance mechanisms and new therapies to overcome it 12
Advances in molecular mechanisms and immunotherapy involving the immune cell-promoted epithelial-to-mesenchymal transition in lung cancer 11
Are erlotinib and gefitinib interchangeable, opposite or complementary for non-small cell lung cancer treatment? Biological, pharmacological and clinical aspects 11
The role of cMET in non-small cell lung cancer resistant to EGFR-Inhibitors: Did we really find the target? 11
Cancer and the microbiome: Potential applications as new tumor biomarker 11
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases? 11
Beyond evidence-based data: Scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma 11
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 11
BIBF 1120/nintedanib: A new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer 11
Androgen receptor in advanced breast cancer: Is it useful to predict the efficacy of anti-estrogen therapy? 11
The cell line models to study tyrosine kinase inhibitors in non-small cell lung cancer with mutations in the epidermal growth factor receptor: A scoping review 10
Concomitant TP53 mutation confers worse prognosis in EGFR-mutated non-small cell lung cancer patients treated with TKIs 10
Replicative Senescence-Associated LINE1 Methylation and LINE1-Alu Expression Levels in Human Endothelial Cells 10
Liquid biopsy for egfr mutation analysis in advanced non-small-cell lung cancer patients: Thoughts drawn from a real-life experience 10
Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer 9
Magnetic Resonance Imaging and 99Tc WBC-SPECT/CT Scanning in Differential Diagnosis between Osteomyelitis and Charcot Neuroarthropathy: A Case Series 9
Well-being among Italian medical oncologists: An exploratory study 9
DNA Methylation-derived biological age and long-term mortality risk in subjects with type 2 diabetes 9
Driver mutations and differential sensitivity to targeted therapies: A new approach to the treatment of lung adenocarcinoma 8
Sex steroids, carcinogenesis, and cancer progression 8
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 8
The Influence of Myeloid-Derived Suppressor Cell Expansion in Neuroinflammation and Neurodegenerative Diseases 8
Petals and thorns in programmed death-ligand 1 testing: Is all non–small cell lung cancer diagnostic material suitable? 8
What can platinum offer yet in the treatment of PS2 NSCLC patients? A systematic review and meta-analysis 7
Progress with palbociclib in breast cancer: Latest evidence and clinical considerations 7
Is Ki67 still a powerful ally in predicting the clinical benefit of anthracyclines for the adjuvant treatment of early breast cancer? 7
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients 7
High-dose chemotherapy in a patient with coronavirus disease (COVID-19) 7
Fully human antibodies for malignant pleural mesothelioma targeting 7
Monoclonal antibodies in gastrointestinal cancers 7
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status 7
Semi-automated volumetric analysis in the NELSON trial for lung cancer screening: Is there room for diagnostic experience yet 7
Dietary restriction: could it be considered as speed bump on tumor progression road? 7
Epithelial-to-mesenchymal transition and EGFR status in NSCLC: The role of vimentin expression 7
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects 7
Impressive clinical response to anti-PD-1 therapy in epithelioid mesothelioma with high clonal PD-L1 expression and EML4-ALK rearrangement 7
Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance? 7
Case Report: Stevens-Johnson Syndrome and Hepatotoxicity Induced by Osimertinib Sequential to Pembrolizumab in a Patient With EGFR-Mutated Lung Adenocarcinoma 7
Epithelial-to-mesenchymal transition in the context of epidermal growth factor receptor inhibition in non-small-cell lung cancer 7
The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial 7
Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: A retrospective analysis 7
Ramucirumab and its use in gastric cancer treatment 7
New generation anaplastic lymphoma kinase inhibitors 6
Management of toxicity induced by anti-EGFR therapy in metastatic colorectal cancer 6
The long and winding road to useful predictive factors for anti-egfr therapy in metastatic colorectal carcinoma: The KRAS/BRAF pathway 6
Multisciplinary management of patients with liver metastasis from colorectal cancer 6
Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis 6
Circulating miR-22, miR-24 and miR-34a as Novel Predictive Biomarkers to Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer 6
Targeted therapies in hepatocellular carcinoma 6
Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors 6
The molecular changes driving the carcinogenesis in Barrett's esophagus: Which came first, the chicken or the egg? 6
How much of familial breast cancer risk is currently explained by the known genes? 6
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 6
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors 6
TMB in NSCLC: A Broken Dream? 6
Predicting efficacy and toxicity in the era of targeted therapy: Focus on anti-EGFR and anti-VEGF molecules 6
Stabilizing versus destabilizing the microtubules: A double-edge sword for an effective cancer treatment option? 6
The role of microRNAs in cancer: Diagnostic and prognostic biomarkers and targets of therapies 6
Molecular target therapy for bone metastasis: Starting a new era with denosumab, a RANKL inhibitor 6
How to find the Ariadne's thread in the labyrinth of salvage treatment options for metastatic colorectal cancer? 6
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 6
What to look for in cell-free DNA from breast cancer patients 6
Prognostic vs predictive molecular biomarkers in colorectal cancer: Is KRAS and BRAF wild type status required for anti-EGFR therapy? 6
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 6
Role of liquid biopsy in oncogene-addicted non-small cell lung cancer 6
HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma 6
Central nervous system involvement in ALK-rearranged NSCLC: promising strategies to overcome crizotinib resistance 6
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 6
Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer? 6
Prognostic and predictive biomarkers for targeted therapy in NSCLC: For whom the bell tolls? 6
Hypoxia and human genome stability: Downregulation of BRCA2 expression in breast cancer cell lines 6
Monoclonal antibodies and antibody fragments: State of the art and future perspectives in the treatment of non-haematological tumors 6
Effects of anti-miR-182 on TSP-1 expression in human colon cancer cells: There is a sense in antisense? 6
Dilemma in metastatic colorectal cancer: VEGF versus EGRF targeting 6
Totale 1.046
Salva come PNG Salva come JPEG
Categoria #
all - tutte 12.879
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 12.879
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202 0 0 0 0 0 0 0 0 0 2 0 0
2020/202115 0 2 0 2 0 3 0 2 3 2 1 0
2021/202214 2 0 5 0 2 0 0 0 1 0 2 2
2022/20235 1 0 1 0 1 0 0 0 0 0 1 1
2023/2024177 0 0 0 3 1 3 1 4 22 7 11 125
2024/2025843 40 104 41 19 212 250 21 46 101 9 0 0
Totale 1.091